Generic Name and Formulations:
Ertapenem (as sodium) 1g; pwd for IV infusion after reconstitution and dilution; or for IM inj after reconstitution; sodium content 6mEq/g.
Merck & Co., Inc.
Indications for INVANZ:
Susceptible moderate to severe infections including complicated intraabdominal, complicated skin and skin structure, community-acquired pneumonia, complicated UTIs, acute pelvic infections. Prevention of surgical site infection following elective colorectal surgery in adults.
Adults and Children:
Do not mix or co-infuse with other meds or diluents containing dextrose. Give by IV infusion over 30 minutes for up to 14 days; or, give by IM inj for up to 7 days (for IM: see note). <3months: not recommended. 3months–12yrs: 15mg/kg twice daily (max 1g/day). ≥13yrs: 1g once daily; renal dysfunction (CrCl ≤30mL/min): 500mg once daily (give supplemental 150mg after session if dosed within 6 hours of hemodialysis). Intraabdominal: treat 5–14 days. Skin and skin structure: treat 7–14 days. Pneumonia, UTIs: treat 10–14 days (may switch to oral antibiotic after 3 days). Pelvic: treat 3–10 days. Adult prophylaxis in colorectal surgery: 1g single IV dose given 1 hour prior to surgical incision.
Penicillin, cephalosporin, or other β-lactam allergy. IM administration in patients with known hypersensitivity to amide-type local anesthetics.
CNS disorders (eg, brain lesions, seizure history). Renal dysfunction. Avoid extravasation. Monitor renal, hepatic, and hematopoetic function in prolonged use. Avoid blood vessel if administering by IM. Elderly. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Potentiated by probenecid: not recommended. Antagonizes valproic acid or divalproex sodium: not recommended; consider other antibacterials.
Diarrhea (evaluate if occurs), nausea, vomiting, inj site reactions (thrombophlebitis/phlebitis), headache, CNS effects (dizziness, altered mental state, rarely: seizures), edema, dyspnea, fever.
For IM use, reconstitute with lidocaine 1% only; see full labeling.
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D